Agentix Corp.

AGTX

US00848A1034

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 11:24:38 2024-03-21 am EDT			5-day change	1st Jan Change
0.0322 ^USD	+0.31%		-.--%	+3.87%

Feb. 14	Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023

November 20, 2023 at 01:03 pm EST

Agentix Corp. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported net loss was USD 0.178972 million compared to USD 0.42433 million a year ago.
For the six months, net loss was USD 0.58853 million compared to USD 0.588984 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.

Latest news about Agentix Corp.

Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 20	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-22	CI
Agentix Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-14	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	23-07-13	CI
Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
Agentix Corp. Reports Earnings Results for the Seven Months Ended March 31, 2022	22-07-18	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	22-07-17	CI
Agentix Corp. Appoints Salman Hoda as Member of the Board of Directors	22-06-14	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	22-04-13	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended November 30, 2021	22-01-13	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	21-10-06	CI
Agentix Corp. completed the acquisition of Applied BioPharma LLC.	21-07-30	CI
Agentix Corp. entered into an Agreement and Plan of Merger to acquire Applied BioPharma LLC.	21-07-13	CI
Agentix Corp. Reports Earnings Results for the Third Quarter Ended May 31, 2021	21-07-09	CI
Agentix Corp. Announces Resignation of Scott Stevens Resigned as A Director	21-06-04	CI
Agentix Corp. Reports Earnings Results for the Second Quarter Ended February 28, 2021	21-03-29	CI
GSL Healthcare, Inc. completed the acquisition of Agentix Corp. in a reverse merger transaction.	20-05-31	CI
GSL Healthcare, Inc. entered into an agreement to acquire Agentix Corp. in a reverse merger transaction for CAD 0.84 million.	20-05-28	CI

Chart Agentix Corp.

Duration

Period

More charts

Company Profile

Agentix Corp. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The Company is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Companyâs wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
AGENTIX CORP.	+3.87%	1.29M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B